Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1976 2
1979 1
1980 5
1981 1
1982 4
1983 11
1984 3
1985 2
1986 5
1987 9
1988 7
1989 8
1990 8
1991 10
1992 17
1993 36
1994 25
1995 38
1996 44
1997 62
1998 37
1999 39
2000 31
2001 20
2002 10
2003 20
2004 16
2005 17
2006 21
2007 13
2008 13
2009 14
2010 24
2011 20
2012 17
2013 18
2014 21
2015 12
2016 7
2017 5
2018 5
2019 4
2020 7
2021 8
2022 7
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 9765336

660 results

Results by year

Filters applied: . Clear all
Page 1
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL. Millan MJ, et al. J Pharmacol Exp Ther. 1998 Oct;287(1):167-86. J Pharmacol Exp Ther. 1998. PMID: 9765336
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G. Millan MJ, et al. J Pharmacol Exp Ther. 1998 Sep;286(3):1341-55. J Pharmacol Exp Ther. 1998. PMID: 9732398
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
Millan MJ, Newman-Tancredi A, Rivet JM, Brocco M, Lacroix P, Audinot V, Cistarelli L, Gobert A. Millan MJ, et al. J Pharmacol Exp Ther. 1997 Jul;282(1):132-47. J Pharmacol Exp Ther. 1997. PMID: 9223549
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Adhumeau A, Brocco M, Nicolas JP, Boutin JA, Despaux N, Peglion JL. Millan MJ, et al. J Pharmacol Exp Ther. 2000 Jan;292(1):38-53. J Pharmacol Exp Ther. 2000. PMID: 10604930
660 results